Although it will be negatively impacted in the short term by the COVID-19 pandemic, the biosurgical agent market in Latin America will grow at a modest rate through 2029, primarily driven by favorable demographics, rising awareness of the clinical benefits of these products on surgical outcomes, and the introduction of new products with enhanced features and expanded indications.
This Medtech 360 Report provides high-level market metrics for biosurgical agents in Latin America, including country-level data for major countries and aggregate data for the rest of the Latin American region, across a 10-year period.
- Biosurgical Agents - Market Insights - Latin America (Supplemental)
Author(s): Sumit Jain, MS Pharm
Sumit Jain is a senior analyst within the Endoscopy, Diagnostics, and Healthcare IT Medtech Insights team at Decision Resources Group, focusing on diagnostic imaging capital equipment and healthcare IT markets. Sumit holds a Bachelor's degree in Pharmacy from the Rajiv Gandhi Technical University, Bhopal, and a Master's degree in Pharmacoinformatics from the National Institute of Pharmaceutical Education and Research, Mohali.